Arvinas Inc
Arvinas Inc (ARVN) Historical Volatility
ARVN's 30 day historical volatility is 65.02%, in the 85th percentile of readings over the past year. This is a high percentile, meaning Arvinas Inc shares have swung far more than usual. ARVN's 30 day implied volatility sits at 171.48%, with an IV Rank of 98.81%, leaving IV 106.46 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 19, 2026.
Read more
Tracking ARVN historical volatility helps you see how much Arvinas Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, ARVN's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor ARVN 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. ARVN's 30 day historical volatility, or ARVN HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing ARVN's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 19, 2026
As of Nov 19, 2026
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →